Clinical Research Puerto Rico. Inc

San Juan 009091711

0 studies enrolling now · 32 studies all time

What they study most

Acute Gastroenteritis, Atopic Dermatitis, Bacterial Skin Diseases, Chronic Genotype 1a or 1b HCV Infection, Chronic Hepatitis C, Diabetes Mellitus, Type 2, Diarrhea, HCV Infection, HIV, HIV Infection, HIV Infections, HIV-1 Infection

Studies at this site

• A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis — Running, not enrolling
• A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone — Completed
• A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer — Stopped early
• A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis — Stopped early
• A Study of LY2623091 in Participants With High Blood Pressure — Completed
• Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study — Completed
• A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes — Completed
• Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF — Completed
• Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults — Completed
• Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) — Completed
• A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol — Stopped early
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus — Completed
• Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment — Completed
• Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access — Completed
• Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir — Completed
• Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF — Completed
• Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections — Completed
• Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon — Completed
• GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection — Completed
• Safety and Efficacy Study of Switching From Epzicom to Truvada — Completed
• Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients — Stopped early
• A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine — Completed
• Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients — Completed
• Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s) — Completed
• A Trial of PEHRG214 in HIV-Infected Patients — Stopped early
• A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy — Completed
• Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients — Completed
• TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1 — Status unconfirmed
• Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients — Paused
• Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy — Completed
• A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients — Completed